Citation(s)
- Baseman JG, Koutsky LA
The epidemiology of human papillomavirus infections. J Clin Virol. 2005 Mar;32 Suppl 1:S16-24. Review.
- Burchell AN, Winer RL, de Sanjosé S, Franco EL
Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006 Aug 31;24 Suppl 3:S3/52-61. Epub 2006 Jun 2. Review.
- Human papillomavirus vaccines
WHO position paper. Wkly Epidemiol Rec. 2009 Apr 10;84(15):118-31. English, French.
- Lim MC, Moon EK, Shin A, Jung KW, Won YJ, Seo SS, Kang S, Kim JW, Kim JY, Park SY
Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010. J Gynecol Oncol. 2013 Oct;24(4):298-302. doi: 10.3802/jgo.2013.24.4.298. Epub 2013 Oct 2.
- Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP)
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee
- Nahar Q, Sultana F, Alam A, Islam JY, Rahman M, Khatun F, Alam N, Dasgupta SK, Marions L, Ashrafunnessa, Kamal M, Cravioto A, Reichenbach L
Genital human papillomavirus infection among women in Bangladesh: findings from a population-based survey. PLoS On
- Parkin DM
The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006 Jun 15;118(12):3030-44.
- Pisani P, Bray F, Parkin DM
Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002 Jan 1;97(1):72-81.
- Sinal SH, Woods CR
Human papillomavirus infections of the genital and respiratory tracts in young children. Semin Pediatr Infect Dis. 2005 Oct;16(4):306-16. Review.
- Weinstock H, Berman S, Cates W Jr
Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004 Jan-Feb;36(1):6-10.
Randomized, Double-Blinded, Active Controlled, Phase I/ II Clinical Trial to Assess the Immunogenicity, Safety, and Tolerability of NBP615 Vaccine in Healthy Female Participants Aged 19 to 26 Years and Adolescent Aged 9 to 13 Years
Details for clinical trial NCT03855150
